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Busulfan and Melphalan with Autologous Stem-Cell
Transplantation in Patients with Refractory
Lymphoid Malignancies
Yago Nieto,1 Peter Thall,2 Ben Valdez,1 Borje Andersson,1 Uday Popat,1 Paolo Anderlini,1
Elizabeth J. Shpall,1 Roland Bassett,2 Amin Alousi,1 Chitra Hosing,1 Partow Kebriaei,1
Muzaffar Qazilbash,1 Erin Frazier,1 Alison Gulbis,1 Christina Chancoco,1 Qaiser Bashir,1
Stefan Ciurea,1 Issa Khouri,1 Simrit Parmar,1 Nina Shah,1 Laura Worth,1 Gabriela Rondon,1
Richard Champlin,1 Roy B. Jones1We developed a new high-dose combination of infusional gemcitabine with busulfan and melphalan for lym-
phoid tumors. Gemcitabine dose was escalated by extending infusions at a fixed rate of 10 mg/m2/min in se-
quential cohorts, in daily, 3-dose or 2-dose schedules. Each gemcitabine dose immediately preceded busulfan
(adjusted targeting area under the curve 4,000 mM/min21/day  4 days) or melphalan (60 mg/m2/day  2
days). We enrolled 133 patients (80 Hodgkin lymphoma [HL], 46 non-Hodgkin lymphoma [NHL], 7 mye-
loma), median 3 prior regimens; primary refractory disease in 63% HL/45% NHL and positron emission
tomography positive tumors at transplantation in 50% patients. Two patients died from early posttransplan-
tation infections. The major toxicity was mucositis. The daily and 3-dose schedules caused substantial cuta-
neous toxicity. In contrast, the 2-dose schedule was better tolerated, which allowed us to extend the
infusions from 15 to 270 minutes. Pretransplantation values of C-reactive protein, B-type natriuretic peptide,
ferritin, or haptoglobin did not correlate with toxicity. Overall response and complete response rates were
87%/62% (HL), 100%/69% B large-cell lymphoma (B-LCL), 66%/66% (T-NHL), and 71%/57% (myeloma). At
median follow-up of 24 months (range, 3-63 months), the event-free/overall survival rates were 54%/72%
(HL), 60%/89% (B-LCL), 70%/70% (T-NHL), and 43%/43% (myeloma). In conclusion, gemcitabine/busulfan/
melphalan is a feasible regimenwith substantial activity against a range of lymphoid malignancies. This regimen
merits further evaluation in phase II and III trials.
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High-dose chemotherapy (HDC) with autologous
stem cell transplantation (autoSCT), using regimens
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oi.org/10.1016/j.bbmt.2012.05.011(BEAM), is standard treatment of patients with che-
mosensitive relapsed Hodgkin lymphoma (HL) and
diffuse large cell lymphoma (DLCL) [1,2]. However,
relapse remains a major problem, particularly in
patients with primary refractory disease or high-risk
features at relapse [3,4]. Populations with a first
remission shorter than 12 months, exposed to
multiple pretransplantation salvage regimens, or with
active tumor at HDC present a 2-year year event-
free survival (EFS) of less than 30% and are in clear
need for more active high-dose regimens [3-7].
Alkylating agents, such as busulfan, constitute the
backbone of HDC regimens based on their steep
concentration-response effect. Precise and predictable
systemic exposure is an important factor of their ther-
apeutic window. The i.v. formulation of busulfan
avoids problems inherent to its oral administration,
such as large interdose variability in absorption or1677
1678 Biol Blood Marrow Transplant 18:1677-1686, 2012Y. Nieto et al.hepatic first-pass effect, and results in markedly
reduced toxicity [8,9]. In a prior study by our group
of an i.v. combination of busulfan and melphalan (Bu/
Mel), prospective targeted adjustment of individual
busulfan doses based on pharmacokinetic (PK)
exposure resulted in absence of veno-occlusive disease
(VOD) [10], with superior tolerability compared with
earlier versions of this 2-drug combination [11]. This
regimen had an antitumor effect in lymphomas at least
comparable to that of BEAM.
Alkylating agent activity depends on the extent
of DNA damage and repair. Thus, combination of
alkylating agents and drugs known to inhibit DNA
damage repair would be predicted to produce additive
or synergistic effects. Gemcitabine is a nucleoside
analogue that has been shown to inhibit DNA damage
repair caused by prior exposure to alkylating agents
[12]. Similar to cytarabine and fludarabine, gemcita-
bine undergoes complex intracellular activating
metabolism, with sequential phosphorylation by deox-
ycytidine kinase (dCK) to its active metabolite difluor-
odeoxycytidine triphosphate (dFdCTP), which is
incorporated into DNA and is considered to be largely
responsible for the cytotoxic effect [13]. Gemcitabine
presents 2 distinct mechanistic advantages over cytar-
abine: it is locked into DNA (‘‘masked chain termina-
tion effect’’) becoming less susceptible to removal by
30-50-proofreading exonucleases, and it inhibits ribo-
nucleotide reductase, which decreases the pool of nor-
mal deoxynucleotide triphosphates competing with
dFdCTP for incorporation into DNA [12]. Preclinical
experiments indicate that the antitumor effect of gem-
citabine is highly dependent on both its dose and dura-
tion of exposure [14-16]. Gemcitabine causes limited
extramedullary toxicity at standard doses and shows
clinical antitumor activity against HL [17,18] and
non-Hodgkin lymphoma (NHL) [19,20]. Therefore,
it presents a promising profile for combination with
alkylators in HDC studies for lymphomas.
Although gemcitabine presents greater affinity than
fludarabine and cytarabine for dCK, this enzyme be-
comes saturated when gemcitabine plasma levels steady
state concentrations (Css) exceed 20 to 30 mmol/L [21].
In contrast, infusing gemcitabine at a fixed dose rate
(FDR) of 10 mg/m2/min seems to minimize the satura-
tion of dCK and optimize dFdCTP formation [22,23].
Randomized trials comparing FDR infusions of
gemcitabine to shorter 30-minute infusions at compara-
ble doses have shown substantial PK advantages for the
FDR schedule, with severalfold greater accumulation of
dFdCTP and increased tumor responses albeit with in-
creased hematological toxicities [24,25]. Autologous
hematopoietic support circumvents myelotoxicity of
HDC, which allows for substantial prolongation of
gemcitabine infusions [26]. We hypothesized that infu-
sional gemcitabine can be safely combined at high doses
with Bu/Mel with autoSCT. We report here the resultsof a dose-finding and schedule-finding study of gem-
citabine, busulfan, and melphalan (Gem/Bu/Mel) in
patients with refractory or poor-risk relapsed lymphoid
malignancies.PATIENTS AND METHODS
Preclinical Studies
Experiments were done to determine the cytotoxic-
ity of Gem/Bu/Mel, individually and in varying combi-
nations. The human lymphoma cell line J45.01 was
obtained from the American Type Culture Collection
(ATCC, Manassas, VA) and grown in RPMI 1640
medium (Mediatech, Manassas, VA) supplemented
with 10% heat-inactivated FBS (Atlanta Biologicals,
Inc., Lawrenceville, GA) and 100 U/mL penicillin
and 100 mg/mL streptomycin at 37C in a humidified
atmosphere of 5% CO2. Busulfan (Sigma-Aldrich, St.
Louis, MO) and melphalan (Sigma-Aldrich) were dis-
solved in DMSO immediately before cellular drug
exposures. The final concentration of DMSO in all
experiments did not exceed 0.08% by volume. Gem-
citabine (Eli Lilly, Indianapolis, IN) was dissolved in
PBS and stored at 4C. Cell suspensions (8 mL of
0.5 106 cells/mL)were grown inT25 flask in the pres-
ence of busulfan, melphalan, or gemcitabine at their
IC10 (15 mg/mL, 0.6 mM, and 0.03 mM, respectively)
or solvent alone and continuously incubated at 37C
for 48 hours. Cell aliquots were then analyzed by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) assay [27]. The remaining cells were
collected by centrifugation, washed with PBS, and lysed
with cell lysis buffer (Cell Signaling Technology,
Danvers, MA) as recommended by the manufacturer.
Total protein concentrations in the cell lysates were
determined using a BCA Protein Assay kit (Thermo
Fisher Scientific, Rockford, IL). Western blot an-
alysis was done by separating protein extracts on
polyacrylamide-SDS gels and blotting onto nitrocellu-
lose membranes (Bio-Rad, Hercules, CA), which were
probed with antibodies against poly ADP-ribose poly-
merase (PARP)1 (Santa Cruz Biotechnology, Inc, Santa
Cruz, CA), g-H2AX (Millipore, Bedford, MA), and
b-actin (Sigma-Aldrich). Immunoblot analyses by
chemiluminescence were done using the Immobilon
Western Chemiluminescent HRP Substrate (Milli-
pore). All cytotoxicity data are the average 6 SD of at
least 4 independent experiments, and all Western blots
were done at least 2 times.
Patient Population
The clinical study protocol was approved by the
Clinical Research Committee and the Institutional
Review Board of MD Anderson Cancer Center, where
all patients were treated. All patients provided written
informed consent to participate in the study.
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Melphalan for Refractory Lymphoid TumorsEligibility included patients ages 18 to 65 with HL
or NHL and primary refractory tumors (defined by
less than complete remission [CR] to first-line treat-
ment or relapse within 3 months), or refractory/
poor-risk relapsed disease, including first CR shorter
than 12 months, more than 1 relapse or progression,
or active tumor at the time of transplantation. Patients
with myeloma were eligible if they had no prior
response to first-line therapy including lenalidomide,
bortezomib, or thalidomide, or relapsed after a prior
autoSCT. Additional eligibility criteria included
adequate renal function (serum creatinine clear-
ance $50 mL/min and/or serum creatinine #1.8
mg/dL), hepatic function (serum glutamic oxaloacetic
transaminase and/or serum glutamic pyruvic transam-
inase#3 upper limit of normal; serum bilirubin and
alkaline phosphatase#2 upper limit of normal), pul-
monary function (forced expiratory volume in 1 sec-
ond, forced vital capacity, and carbon monoxide
diffusing capacity $50%), and cardiac function (left
ventricular ejection fraction $40% without uncon-
trolled arrhythmias or symptomatic cardiac disease),
a Zubrod performance status 0-1, no evidence of un-
controlled infection, no prior whole brain irradiation,
and no radiation therapy in the month before enroll-
ment. Patients with active hepatitis B were excluded.
Patients with chronic hepatitis C or positive hepatitis
C serology were excluded if they had evidence of either
cirrhosis or stage 3-4 liver fibrosis. Patients with HL
and NHL and a prior autologous transplantation
were not eligible. Patients were not eligible for enroll-
ment until their nonhematologic toxicity from previ-
ous therapies had downgraded to at least grade 1.
Restaging studies were obtained within 30 days
before enrollment and subsequently at 1 month,
3 months, 6 months after SCT, and every 6 months
thereafter as feasible. Responses were assessed before
any planned post-HDC treatment, at 1 month for
patients with HL and NHL and at 3 months for
patients with myeloma. Staging studies for patients
with HL and NHL included computed tomography
and positron emission tomography (PET) scans,
which were interpreted using mediastinal blood
pool activity as the reference background [28] and
bone marrow (BM) biopsy when applicable. Patients
with myeloma had serum and urine electrophoresis,Table 1. Treatment Schedule
Day 210 29 28 27 2
Gemcitabine Daily X X
3-dose X
2-dose X
Busulfan x (test) X X
Melphalan
PBPC
Rituximab (CD20+ tumors)
PBPC indicates peripheral blood progenitor cells.quantitative immunoglobulin, free light chain studies,
BM biopsy, and bone survey. C-reactive protein
(CRP), B-type natriuretic peptide (BNP), ferritin,
haptoglobin, and troponin in serum were measured
at the time of admission.
High-Dose Chemotherapy
The treatment schema is shown in Table 1.
Patients received an i.v. test dose of busulfan of 32
mg/m2 over 45 minutes on day210. The conditioning
regimen started on day28. Three schedules of gemci-
tabine were tested: daily 6 (days28 to25, and23 to
22), 3 doses (days 28, 26 and 23), and 2 doses (days
28 and 23). Each dose of gemcitabine was adminis-
tered as a loading bolus of 75mg/m2, targeting a steady
state concentration of 15 mmol/L followed by a contin-
uous infusion per cohort, and immediately followed by
the corresponding dose of busulfan or melphalan.
Busulfan was infused daily over 3 hours from days
28 to 25 targeting an average daily area under the
curve (AUC) of 4,000 mM/min21, with the first 2 ther-
apeutic doses calculated from the PK parameters
derived from the prior test dose. If necessary, a dose
adjustment for the third and fourth doses was made
after the analysis of the first therapeutic dose, targeting
an aggregate AUC of 16,000 mM/min21. The sam-
pling process and analytical methodology have been
previously described [10]. In cases in which PK dosing
of busulfan was not feasible, patients received a fixed
daily dose of 105 mg/m2. After a day of rest on day
24, melphalan was administered at 60 mg/m2 daily
over 30 minutes on days 23 and 22.
Supportive Care
Acetaminophen, azoles, and metronidazole were
avoided from day 210 to 21. Phenytoin 600 mg oral
daily was started the evening before the test dose of
busulfan until 24 hours after the last dose of busulfan.
Hydration with 0.9% saline was administered at
125mL/hour from admission until day21. Supportive
oral care was uniform using palifermin (60 mcg/kg/
d i.v., days213 to211 and 0 to12), oral cryotherapy
throughout each melphalan infusion, and oral and
throat rinses with caphosol (30 mL 4 times a day)
and glutamine (15 g 4 times a day). The infusion of6 25 24 23 22 21 0 +1 +8
X X X X
X X
X
X X
X X
X
X X
Table 2. Toxicities Per Dose Level (2-Dose Schedule)
Level N
Gem Infusion
(min)
Gem Dose
(mg/m2)
Mucositis Skin
DLTG2 G3 G2 G3
1 3 15 225 33% 0 0 0 0%
2 3 40 475 0 0 0 0 0%
3 3 60 675 33% 0 0 0 0%
4 6 90 975 80% 0 0 0 0%
5 14 120 1275 59% 23% 12% 0 6%
6 22 180 1875 71% 6% 18% 0 2%
7 14 210 2175 60% 27% 33% 0 7%
8 14 240 2475 64% 28% 21% 7% 7%
9 (MTD) 50 270 2775 54% 28% 18% 3% 14%
Gem indicates gemcitabine; DLT, dose-limiting toxicity; MTD, maximum
tolerated dose.
Figure 1. Cytotoxicity of gemcitabine/busulfan/melphalan (Gem/Bu/
Mel) on chemotherapy-resistant J45.01 cells. (A) Cell proliferation. (B)
Immunoblot staining. Bu or B, busulfan; Mel or M, melphalan; Gem or
G, gemcitabine, BM, bone marrow; PARP1, poly ADP-ribose polymer-
1680 Biol Blood Marrow Transplant 18:1677-1686, 2012Y. Nieto et al.peripheral blood progenitor cells (PBPC) was on day
0. Granulocyte macrophage-colony stimulating factor
was administered at a dose of 5 mcg/kg/day subcutane-
ously beginning on day 15 until neutrophil recovery.
Institutional transplantation guidelines for anti-
emetics, antibacterial, antifungal and antiviral prophy-
laxis, and red blood and platelet transfusions were
followed.ase; BG, busulfan/gemcitabine; MG, melphalan/gemcitabine; BMG,
busulfan/melphalan/gemcitabine; Rel, relative.Trial Design
The primary endpoints were to determine the
optimal schedule and maximum tolerated dose
(MTD) of gemcitabine when added to Bu/Mel and
to define the dose-limiting toxicity. Secondary end-
points were to describe the toxicity profile of the new
regimen and to derive preliminary estimates of EFS
and overall survival (OS) produced by this regimen.
In this schedule-finding and dose-finding study,
gemcitabine was combined with fixed doses of Bu/
Mel. Dose levels were determined by prolonging the
infusion of gemcitabine by prespecified time intervals
maintaining its infusion rate (Table 2). Patients were
assigned a dose level using the continual reassessment
method [29], based on the toxicity data available at the
time of their enrollment targeting a dose-limiting
toxicity (DLT) probability closest to 0.15. Toxicities
were scored according to the National Cancer Insti-
tute Common Toxicity Criteria, version 3.0 [30].
DLT was defined as grade 3 mucositis or skin toxicity
lasting for more than 3 days before downgrading, or as
any grade 4 or 5 nonhematologic toxicity. After the
daily and 3-dose schedules were found to be exces-
sively toxic at their starting levels, dose escalation
proceeded on the 2-dose schedule with 6 initially
planned dose levels (levels 1-6). After level 6 was estab-
lished as safe, the protocol was amended to escalate
above this level. After the MTD was identified at level
9, this level was expanded to a total of 50 patients to
fully characterize its side effect profile. The method
of Thall et al. [31] was used to perform the interim
monitoring.Statistical Analyses
Results of the cytotoxicity assay were compared
using the t test. For categorical variables, the Fisher
exact test and its generalizations were used to assess
association with grade 3 toxicities. All P values are
2-sided. No adjustment of P values for multiple com-
parisons was performed.
Overall response rate (RR) and complete response
rates were calculated among patients with measurable
disease at the time of HDC following the usual criteria
[32,33]. The EFS was defined as the time from
transplantation to either relapse or death, whichever
occurred first, or to last contact. OS was defined as
the time from transplantation to death or last
contact. Kaplan-Meier survival curves were used to
estimate unadjusted time-to-event distribution (EFS
and OS) [34]. All calculations used R v2.12.1 and
OpenBUGS v3.1.2 rev 668.RESULTS
Preclinical Experiments
Exposure of J45.01 cells individually to busulfan,
melphalan, or gemcitabine did not show significant
effects on cell proliferation (Figure 1A). Two-drug
combinations (Bu/Mel, gemcitabine/busulfan, or
gemcitabine/melphalan) resulted in mean inhibition
of proliferation of 16%, 18%, and 22%, respectively.
Exposure of this refractory cell line to Gem/Bu/Mel
resulted in an average 48% inhibition of proliferation,
Table 3. Patient Characteristics (N 5 133)
Age: median (range) 41 (18-65)
Gender: male/female 77/56
Hodgkin lymphoma (N 5 80)
Primary refractory 53
Relapsed 27
Remission #1 yr 72 (90%)
Extranodal disease at relapse/PD 40 (50%)
B symptoms at relapse/PD 11 (14%)
No. clinical risk factors*
1 20 (25%)
2 43 (56%)
3 17 (21%)
No. prior relapses/PD:
1 46 (57%)
>1 34 (43%)
Bulky tumor at relapse/PD 29 (36%)
Prior treatment
No. prior chemotherapy regimens: median (range) 3 (2-6)
Prior radiotherapy 22
Disease status at HDC
Clinical response: CR/PR/PD 39/18/23
PET: positive/negative 41/39
NHL (N 5 46)
B-LCL 30
Primary DLCL 18
Transformed 4
Primary CNS LCL 4
Primary mediastinal LCL 4
Burkitt lymphoma 3
Follicular lymphoma 2
T-NHL 11
Anaplastic large cell 6
Peripheral TCL NOS 2
NK/T 2
Angioimmunoblastic 1
Primary refractory (B-LCL/FL/BL/T-NHL) 21
Relapsed (B-LCL/FL/BL/T-NHL) 25
Time to relapse
#12 mo 19
>12 mo 6
No. prior relapses/PD
1 23
>1 23
Secondary IPI†
0-1 7 (17%)
2-3 25 (62%)
>3 8 (20%)
Elevated LDH at relapse/PD 13
Prior treatment
No. prior chemotherapy regimens: median (range) 3 (2-9)
Prior radiotherapy 10
Disease status at HDC
Clinical status: CR/PR/PD 21/14/11
PET status: positive / negative 23/23
Myeloma (N 5 7)
Primary refractory 4
Relapsed and refractory 3
No. prior relapses relapses/PD
1 3
>1 4
Stage III 7
Poor-prognosis CGA† 3
Prior treatment
No. prior chemotherapy regimens: median (range) 3 (2-5)
Prior radiotherapy 3
Disease status at HDC
Clinical status: CR/PR/PD 0/2/5
PD indicates progressive disease; HDC, high-dose chemotherapy; CR,
complete response; PR, partial response; PET, positron emission tomog-
raphy; NHL, non-Hodgkin lymphoma; B-LCL, B large-cell lymphoma;
DLCL, diffuse large cell lymphoma; CNS, central nervous system;
LCL, large cell lymphoma; T-NHL, T non-Hodgkin lymphoma; PTCL, pe-
ripheral T cell lymphoma; NOS, not otherwise specified; NK/T, natural
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binations (P values\ .001). To determine a possible
mechanism of the cytotoxicity of Gem/Bu/Mel,
immunoblot staining was performed. Exposure to
Gem/Bu/Mel produced increased cleavage of PARP1
and phosphorylation of histone 2AX (Figure 1B),
indicative of activation of apoptosis, and increased
DNA damage response, respectively.
Patient Enrollment
One hundred thirty-three patients were enrolled
between January 2007 and August 2011 (Table 3).
Their median age was 41 (range, 18-65 years). Eighty
patients had HL, 46 had NHL (35 B lymphomas and
11 T lymphomas), and 7 had myeloma. No patients
received a prior autoSCT but were heavily pretreated
with a median of 3 prior regimens (range, 2 to 9).
Thirty-five patients with HL and 6 patients with
NHL had previously received gemcitabine. Patients
had extensive tumor involvement (median, 3 organs).
In the HL subgroup, extranodal disease, B symptoms,
and a bulky nodal mass (.5 cm) were present in 50%,
14%, and 36% of patients, respectively, and 43% of
patients had more than 1 prior relapse. In the NHL
subgroup, an International Prognostic Index at the
time of relapse of 0-1, 2-3, or .3 was present in
17%, 62%, and 20% of patients, respectively, and
50% of patients had more than 1 prior relapse. Half
of all patients with HL and NHL had PET-positive
tumors at the time of HDC. Almost 30% of all
enrolled patients (23 patients with HL, 11 with
NHL, and 5 with myeloma) had progressive disease
at the time of admission.
Hematologic Recovery
The source of stem cells was peripheral blood for
all patients. The median times to neutrophil and plate-
let engraftment were 9 days (range, 8-12 days) and
11 days (range, 8-31 days), respectively.
Regimen-Related Toxicities
The daily and 3-dose schedules of gemcitabine
resulted in excessive cutaneous and mucosal toxicity at
their starting levels. One of 2 patients on the daily
schedule and both patients on the 3-dose schedule
developed G4 bullous dermatitis. Toxicity was mark-
edly reduced in the 2-dose schedule, which allowed
escalation of gemcitabine infusion from level 1
(15-minute infusion, daily dose, and total dose of 225
and 450 mg/m2, respectively) to level 9 (4.5-hourkiller/T cell; FL, follicular lymphoma; BL, Burkitt’s lymphoma; IPI, Interna-
tional Prognostic Index; LDH, lactate dehydrogenase; CGA, cytogenetic
abnormality.
*Risk factors: B symptoms at relapse, extranodal disease (both at
relapse), or remission duration <1 year.
†Poor-prognosis CGA: 17p deletion, t(14;16), t(4;14), and 13 deletion.
1682 Biol Blood Marrow Transplant 18:1677-1686, 2012Y. Nieto et al.infusion, daily dose of 2,775 mg/m2, total dose 5550
mg/m2), which was established as the MTD (Table 3).
After the MTD was identified at level 9 with mucositis
being the DLT, this level was expanded to a total of 50
patients to fully characterize its toxicity profile. No
regimen-related deaths or G4 toxicities were seen on
the 2-dose schedule, which was associated with the fol-
lowing side effect profile:
Mucositis
G2 to 3 mucositis was common at dose level 4 and
above. It started at median day 14 (range, day 11 to
17) and lasted at its maximal severity for a median of
2 days (range, 1-8 days). Sixty-five percent of patients
required a narcotic patient-controlled analgesia
pump for a median of 6 days (range, 3-17 days).
Skin effects
An early G1 to 2 erythematous rash was common
and resolved within a few days of using over-the-
counter sunburn creams (eg, Noxzema) or topical ste-
roids. Two patients who developed a G3 rash received
a short course of i.v. methylprednisolone at 1 mg/kg/d.
Hepatic effects
An early and self-limited elevation of transaminases
was common (75%patients) across all dose levels, start-
ing on median day 1 (range, day 6-0), peaking at a me-
dian value of 124 IU/L (range, 41-1120 IU/L) and
resolving within 1 week. A transient bilirubin elevation
was seen in 11% of patients in the first week posttrans-
plantation (median peak of 2.4, 1.6-4.4 mg/dL). There
were no cases of VOD.
Pulmonary effects
There were 2 cases of steroid-responsive G2 pneu-
monitis, in levels 6 and 9, respectively, both in patients
with previous mantle field radiotherapy. Four addi-
tional patients had asymptomatic infiltrates on day
130 restaging computed tomography scans with neg-
ative microbiological studies on bronchioalveolar
lavage. They promptly resolved spontaneously and
were attributed toG1 pneumonitis. There were no sig-
nificant DLCO changes in the study population from
before (median 75% of predicted, 53%-113%) to
1 month posttransplantation (median 77%, 38%-
113%; P 5 .75).
Other toxicities
Diarrhea was mild with only 8G2 cases. There was
1 case of G2 renal toxicity. No neurological or cardiac
toxicities were observed.
The median values on admission of CRP, BNP,
ferritin, and haptoglobin were 7 mg/L (range, 0.35-
189 mg/L), 79 pg/mL (range, 7-612 pg/mL), 330 ng/
mL (range, 9-15,063 ng/mL), and 82 mg/dL (range,9-446mg/dL), respectively. All patients had a troponin
value of 0 on admission. There were no differences be-
tween patients who experienced G3 toxicity in the
2-day schedule and those who did not with respect to
values of C-reactive protein (P 5 .90), B-atrial natri-
uretic peptide (P5 .40), ferritin (P5 .20), or haptoglo-
bin (P5 .30). Likewise, none of the following variables
predicted occurrence of G3 toxicity in the 2-day
schedule: dose level below the MTD, number of prior
lines of therapy, number of organs involved, or diagno-
sis. There seemed to be a higher incidence of G3 tox-
icities among patients younger than 41 years not
reaching statistical significance (31% vs 17%; P5 .06).
Infections
Two patients experienced fatal infections: 1 with
Candida albicans sepsis in the setting of severe grade 4
mucositis (daily schedule) and 1 with Pseudomonas
aeruginosa pneumonia (2-dose schedule). The latter in-
fection had been previously diagnosed and treated be-
fore transplantation but reoccurred fatally during
myelosuppression. The following additional infections
resolved with antimicrobials: E coli bacteremia (N5 2),
K pneumoniae bacteremia (N 5 1), S epidermidis bacter-
emia (N 5 2), C difficile-positive diarrhea (N 5 2),
RSV pneumonia (N 5 1), and E faecalis urinary tract
infection (N 5 1).
Busulfan PK Studies
Busulfan PK parameters were calculated from
blood samples of 121 patients (91% of the study file).
These patients had their first and second therapeutic
doses determined based on the PK analyses after the
test dose, and their third and fourth doses subsequently
adjusted based on the PK analyses after the first dose. In
7% of patients, dose 1 AUCwasmore than 20%higher
(N5 3) ormore than 20% lower (N5 4) than the value
predicted after the test dose. For the remaining 93% of
patients, the interdose variation of calculated clearance
estimates between the test dose and the first therapeutic
dose was less than 20%. The overall mean of the vari-
ation of the calculated test-to-therapeutic clearance
was 8.3% (95% confidence interval, 211% to 28%).
The mean population clearance (% coefficient of vari-
ation), volume of distribution, and plasma half-life for
once-daily dosing were 99 mL/min/m2 (16.7%),
25 L/m2 (14%), and 2.9 hours (16.8%) from the first
therapeutic dose. These data did not differ significantly
from those previously estimated with Bu/Mel [10], in
which themean clearance of busulfan after its first ther-
apeutic dose was 97.9 mL mL/min/m2 (15.7%)
(P5 .60), which indicates an absence of PK interaction
of gemcitabine on busulfan. The mean and median
daily AUCs from the first therapeutic dose in the pres-
ent study were 3,726 and 3,666 mMolmin (95% con-
fidence interval, 2,825-4,625), respectively.
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Figure 2. Event-free survival (EFS) and overall survival (OS) of themain
histologic subsets. (A) Hodgkin lymphoma. (B) B-large cell lymphoma.
Post-HDC, high-dose chemotherapy.
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Tumor responses in patients with HL and NHL
were assessed at 1 month post-HDC. Among 41
patients with HL and measurable disease, the com-
plete response and RR were 62% and 88%, respec-
tively. There were no significant differences per
previous gemcitabine exposure. The RR was 100%,
88%, 80%, and 90%, respectively, among patients
with a prior complete response, prior partial response,
no previous response, and no prior gemcitabine. Like-
wise, complete response rates did not vary significantly
among those subgroups (50%, 75%, 60%, and 67%,
respectively).
All 17 patients with B-LCL with measurable dis-
ease responded, with 15 complete responses. Both
patients with follicular lymphoma (FL) had a complete
response. Three patients with primary refractory Bur-
kitt lymphoma had a complete response. Two of 3 pa-
tients with T-NHL and measurable tumors
(angioimmunoblastic and peripheral T cell lymphoma,
respectively) had a complete response; a third patient
(with anaplastic large-cell lymphoma) experienced
short-lived tumor shrinkage that did not meet re-
sponse criteria. Of note, all 6 patients with NHL
with prior gemcitabine treatment, none of whom had
previously responded to this drug, had a complete re-
sponse after Gem/Bu/Mel.
Finally, all 7 patients with myeloma had measur-
able disease: 5 of them responded, 4 of them with
a complete response at 3 months.
Post-HDC Treatment
Twenty-eight patients (21 with HL, 7 with NHL)
who had bulky (.5 cm) PET-positive lesions received
radiotherapy to their PET-positive sites starting at 1 to
2 months after transplantation at 30.6-41.4 Gy. Post-
transplantation radiotherapy was well tolerated from
hematological and nonhematological standpoints.
Irradiated sites included mediastinum, axillary/supra-
clavicular lymph nodes, thoracic spine, mesentery, ret-
roperitoneum, and nasopharynx. Two patients with
refractory DLCL underwent a planned matched unre-
lated donor nonmyeloablative transplantation around
3 months after Gem/Bu/Mel. One of them died from
complications of the allogeneic procedure, whereas
the other patient tolerated it without difficulty.
Three patients with myeloma received mainte-
nance lenalidomide.
Patient Outcomes
Median follow-up of the whole study population
was 24 months (range, 3-63 months). The EFS and
OS rates of the HL subgroup are 54% and 72%,
respectively, with median EFS of 43 months and
median OS not reached (Figure 2A). Forty-three pa-
tients are alive in complete response at 6 to 60 monthsafter HDC, including 16 of 21 patients treated at the
MTD. Thirty-seven patients experienced tumor
relapse after HDC, and 20 of these died from relapse.
Eighteen of 30 patients with B-LCL (60%) are
alive in complete response, including 11 of 18
DLCL, 3 of 4 transformed LCL, 2 of 4 primary medi-
astinal LCL, and 2 of 4 primary central nervous system
LCL (Figure 2B). Twelve of 24 patients with B-LCL
treated at the MTD are in complete response. Six
of 11 patients with T-NHL are alive in complete
response (4 of 6 anaplastic large-cell lymphoma
[ALCL], 1 of 2 peripheral T-cell lymphoma
[PTCL], 2 of 2 natural killer/T [NKT] and 0 of 1 an-
gioimmunoblastic). One of the 2 patients with follicu-
lar lymphoma is alive in complete response at 15
months after HDC; the other patient is alive with re-
lapsed disease. All 3 patients with Burkitt lymphoma
experienced rapid tumor relapse and died shortly after
HDC. Last, 3 of the 7 patients with myeloma are alive
and free of progression at 46 to 48 months (1 complete
response, 2 stable residual disease), and 4 patients died
from relapse of their disease.DISCUSSION
Our study shows that high doses of infusional gem-
citabine can be safely added to Bu/Mel with autoSCT.
The optimal schedule includes 2 doses of gemcitabine,
each one preceding the first doses of Bu/Mel, respec-
tively, which caused a manageable side effect profile
of stomatitis and skin rash. Busulfan PKs were similar
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indicates no PK interaction of gemcitabine on busul-
fan. The resulting regimen presented high antitumor
activity in the population of patients with refractory
or poor prognosis relapsed lymphomas enrolled.
In lymphomas, as in other tumor types, 2 major
factors determine the clinical activity of gemcitabine
and other nucleoside analogs: substrate specificity for
their activating nucleoside kinases and the expression
of these enzymes in tumor tissues. The content of
dCK, the rate-limiting enzyme in the activation of
pyrimidine analogs, is severalfold higher in lympho-
cytes than in epithelial cells, and in most tumor tissues
compared to their normal counterparts [35,36]. The
affinity of dCK for gemcitabine is higher than for
fludarabine, cytarabine, or cladribine, which may
account for its broader spectrum of activity [12]. How-
ever, this enzyme becomes saturated at high intracellu-
lar levels of gemcitabine [21]. Furthermore, when
present at high intracellular levels, parental gemcita-
bine acts as a substrate inhibitor of dCK [37]. These
observations seem to be the basis for the decline in
the ability of the cells to accumulate dFdCTP at gem-
citabine, concentrations above 20 mmol/L. As a conse-
quence, merely increasing the dose of gemcitabine in
a standard 30-minute infusion will augment its extra-
cellular and intracellular concentrations but will not re-
sult in a parallel increase of the active metabolite
dFdCTP. Whereas prolonged infusions of gemcita-
bine, optimizing dFdCTP formation, seem its most
pharmacologically rational administration schedule
[23], their clinical applicability is hampered by in-
creased myelotoxicity [24,25]. Phase 1 studies
exploring dose escalation of gemcitabine infused at
FDR were limited by myelosuppression [38-40]. In
contrast, autoSCT allowed us in a prior trial to
circumvent myelotoxicity and fully dose escalate
gemcitabine in multiple 4-hour infusions combined
with a high-dose triplet of docetaxel/melphalan/carbo-
platin [26]. The resulting regimen was feasible and
markedly active against refractory solid tumors. We
observed a dose-linear PK behavior of parental gemci-
tabine and prolonged intracellular retention times of
dFdCTP, which accounted, at least in part, for the pre-
dictable side effects of that regimen. Furthermore, we
measured exponential increases of intracellular
dFdCTP levels over the course of repeated doses of
gemcitabine, consistent with its known mechanisms
of metabolic self-potentiation. Those observations
prompted us to further explore infusional gemcitabine
specifically targeting lymphomas. Building on prior
work from our group and others with i.v. busulfan/nu-
cleoside analogue regimens [41,42], we used Bu/Mel
as an alkylator platform for combination with
gemcitabine. Our preclinical experiments showing
greater cytotoxicity with Gem/Bu/Mel provided the
basis, albeit their normoxic conditions and otherlimitations of in vitro studies, for using these 3 drugs
combined.
We designed Gem/Bu/Mel based on the overrid-
ing principles of using a prolonged infusion schedule
of gemcitabine in a sequence that would facilitate syn-
ergism with Bu/Mel based on inhibition of DNA dam-
age repair [12,43]. In addition to this well-established
synergy mechanism, we have recently reported that
gemcitabine induces chromatin relaxation, increasing
DNA access and cytotoxicity of busulfan in lymphoma
cell lines [44]. Confirming our hypothesis, we saw high
activity of Gem/Bu/Mel in the population of heavily
pretreated and refractory patients with HL, B-NHL,
and T-NHL enrolled in this trial. At median follow-
up of 2 years, their EFS rates are 54%, 60%, and
55%, respectively. T and B lymphocytes express
dCK at high levels [45], which likely contributes to
these results. Although longer follow-up is needed,
these outcomes are encouraging, as most posttrans-
plantation relapses in similarly high-risk populations
typically occur early after transplantation.
Because we treated a small number of patients with
myeloma, no conclusions can be drawn about the ac-
tivity of Gem/Bu/Mel in this tumor. Gemcitabine
has potent activity against myeloma cell lines
in vitro, including cells resistant to other drugs
[46,47]. Unfortunately, gemcitabine has not been
adequately tested clinically in this disease. In a small
phase 2 trial of weekly 30-minute infusions, little activ-
ity was observed against refractory tumors [48]. As in
other preclinical models, gemcitabine cytotoxicity
against myeloma cells correlates with dFdCTP
intracellular accumulation [46]. Whereas myeloma
plasma cells have been shown to express dCK [49],
gene profile studies indicate lower expression than
normal for malignant B/T lymphocytes [50,51]. This
strengthens the rationale for studying gemcitabine in
prolonged infusions in myeloma.
Toxicities of this regimen depended on the gemci-
tabine schedule and dose. The daily and 3-dose sched-
ules had substantially more cutaneous toxicity than the
2-dose schedule. Mucositis was the DLT, and its inci-
dence (54% G2 and 28% G3 at the MTD) seemed
increased compared to our prior study with Bu/Mel
(49% G2 and 7% G3). We considered dose level 9
using the 2-dose schedule to be the MTD to take
forward into phase II and III studies.
It would be useful to identify predictive markers of
severe toxicity. Previous reports have correlated high
pretransplantation values of the inflammatory bio-
markers CRP and ferritin (which is also a maker of
iron overload) with G3-4 toxicity in patients receiving
allogeneic and autologous stem cell transplantations,
respectively [52-55]. Likewise, levels of haptoglobin,
another acute phase protein, have been inversely
associated with hematological toxicity of gemcitabine
at standard doses [56]. High pretransplantation values
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were associated with hepatic VOD and treatment-
related mortality in a study in allogeneic SCT [57].
We could not identify any serum marker or patient-
related characteristic associated with G3 or greater
toxicity after Gem/Bu/Mel. It is possible that poly-
morphic genetic variation of relevant enzymes
involved in the metabolism of these drugs might
predict toxicity.
In conclusion, the dose of gemcitabine can be sub-
stantially escalated at an infusion rate that optimizes its
intracellular activation, in combination with Bu/Mel
with autoSCT. This regimen induced high response
and complete response rates in patients with refractory
or poor prognosis HL and NHL with encouraging
preliminary outcome results. Further investigation of
this regimen is underway in disease-specific studies.ACKNOWLEDGMENTS
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